{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T04:22:17Z","timestamp":1726806137411},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Brandenburg CAMPUS GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chirurgie"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Klinische Krebsregister sollen durch differenzierte Datenauswertung die Versorgungsrealit\u00e4t abbilden und ggf. Ans\u00e4tze f\u00fcr Verbesserung der Versorgung bieten.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methode<\/jats:title>\n                <jats:p>F\u00fcr die Jahre 2000 bis 2018 wurden die Daten des klinisch-epidemiologischen Krebsregisters Brandenburg-Berlin bez\u00fcglich Epidemiologie und Versorgungsrealit\u00e4t getrennt nach Adeno- und Plattenepithelkarzinom untersucht.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Zwischen 2000 und 2018 wurden 3207 \u00d6sophaguskarzinome im Krebsregister dokumentiert, davon waren 2182 Plattenepithelkarzinome (ESCC), 843 Adenokarzinome (EAC) und 182 verschiedene andere oder fehlende Histologien. Im Beobachtungszeitraum zeigte sich eine deutliche Dominanz der ESCC, jedoch mit einer signifikanten Zunahme der EAC bei beiden Geschlechtern. Die Neuerkrankungsrate war insgesamt f\u00fcr M\u00e4nner 5fach h\u00f6her als f\u00fcr Frauen. Die relative 5\u2011Jahres-\u00dcberlebenswahrscheinlichkeit aller \u00d6sophaguskarzinome lag bei M\u00e4nnern bei 17,4\u202f% und bei Frauen bei 22,5\u202f%. Patienten mit EAC \u00fcberlebten signifikant l\u00e4nger als mit ESCC. Als Therapiemethoden kamen \u00fcberwiegend Strahlen- und Chemotherapie, einzeln oder in Kombination, zum Einsatz. Operiert wurden 19\u202f% der Plattenepithel- und 42\u202f% der Adenokarzinome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>Der Anteil der ESCC ist in Brandenburg immer noch deutlich h\u00f6her als der der EAC, wobei f\u00fcr Letztere, insbesondere bei M\u00e4nnern, ein signifikanter Anstieg zu verzeichnen ist. Obwohl lokal fortgeschrittene Tumoren deutlich h\u00e4ufiger auftraten, sind moderne neoadjuvante Konzepte bisher selten dokumentiert und obwohl die Qualit\u00e4t der Operationen mit dem internationalen Standard vergleichbar ist, werden nur relativ wenige Patienten operiert.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00104-024-02110-0","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T15:31:27Z","timestamp":1718119887000},"page":"825-832","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Versorgungsrealit\u00e4t des \u00d6sophaguskarzinoms im Bundesland Brandenburg","Treatment reality of esophageal cancer in the Federal State of Brandenburg"],"prefix":"10.1007","volume":"95","author":[{"given":"Andreas","family":"Loew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constanze","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maren","family":"Pfl\u00fcger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Mantke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karsten H.","family":"Weylandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Gretschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"key":"2110_CR1","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran\u00a0SE, Homann\u00a0N, Pauligk\u00a0C et\u00a0al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a\u00a0randomised, phase\u00a02\/3\u00a0trial. Lancet 393:1948\u20131957","journal-title":"Lancet"},{"key":"2110_CR2","unstructured":"Anonymous (2022) Cancer-Stat-Facts Esophageal Cancer. https:\/\/seer.cancer.gov"},{"key":"2110_CR3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang\u00a0YJ, Van Cutsem\u00a0E, Feyereislova\u00a0A et\u00a0al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a\u00a0phase\u00a03, open-label, randomised controlled trial. Lancet 376:687\u2013697","journal-title":"Lancet"},{"key":"2110_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/jso.20569","volume":"94","author":"E Bollschweiler","year":"2006","unstructured":"Bollschweiler\u00a0E, Baldus\u00a0SE, Schr\u00f6der\u00a0W et\u00a0al (2006) Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors? J\u00a0Surg Oncol 94:355\u2013363","journal-title":"J Surg Oncol"},{"key":"2110_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki\u00a0Y, Ajani\u00a0JA, Kato\u00a0K et\u00a0al (2022) Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N\u00a0Engl J Med 386:449\u2013462","journal-title":"N Engl J Med"},{"key":"2110_CR6","unstructured":"https:\/\/www.basisdatensatz.de\/download\/basisdatensatz12.7.Pdf"},{"key":"2110_CR7","unstructured":"https:\/\/www.krebsgesellschaft.de\/jahresberichte.html"},{"key":"2110_CR8","unstructured":"Krebsregisterdaten ZF (2019) https:\/\/www.krebsdaten.de\/krebs\/DE\/content\/krebsarten\/speiseroehrenkrebs\/speiseroehrenkrebs"},{"key":"2110_CR9","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"H Luo","year":"2021","unstructured":"Luo\u00a0H, Lu\u00a0J, Bai\u00a0Y et\u00a0al (2021) Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st\u00a0Randomized Clinical Trial. JAMA 326:916\u2013925","journal-title":"JAMA"},{"issue":"42","key":"2110_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan\u00a0E, Soerjomataram\u00a0I, Rumgay\u00a0H et\u00a0al (2022) The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology 163(42):649\u2013658.e6","journal-title":"Gastroenterology"},{"key":"2110_CR11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/SLA.0b013e318188c474","volume":"248","author":"CG Peyre","year":"2008","unstructured":"Peyre\u00a0CG, Hagen\u00a0JA, Demeester\u00a0SR et\u00a0al (2008) The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 248:549\u2013556","journal-title":"Ann Surg"},{"key":"2110_CR12","unstructured":"Robert-Koch-Institut (2022) Zentrum f\u00fcr Krebsregisterdaten. https:\/\/www.krebsregisterdaten.de"},{"key":"2110_CR13","unstructured":"Seer-Data-Base (2022) Cancer-Stat-Facts Esophageal cancer. https:\/\/seer.cancer.gov"},{"key":"2110_CR14","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun\u00a0JM, Shen\u00a0L, Shah\u00a0MA et\u00a0al (2021) Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a\u00a0randomised, placebo-controlled, phase\u00a03\u00a0study. Lancet 398:759\u2013771","journal-title":"Lancet"},{"key":"2110_CR15","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/SLA.0000000000003636","volume":"274","author":"WBJ Van Der","year":"2021","unstructured":"Van Der\u00a0WBJ, Noordman\u00a0BJ, Neijenhuis\u00a0LKA et\u00a0al (2021) Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A\u00a0Multicenter Propensity Matched Study. Ann Surg 274:1009\u20131016","journal-title":"Ann Surg"},{"key":"2110_CR16","first-page":"Cd004064","volume":"8","author":"AD Wagner","year":"2017","unstructured":"Wagner\u00a0AD, Syn\u00a0NL, Moehler\u00a0M et\u00a0al (2017) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 8:Cd4064","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Die Chirurgie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-024-02110-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00104-024-02110-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-024-02110-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T13:09:13Z","timestamp":1726751353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00104-024-02110-0"}},"subtitle":["Ein Vergleich zwischen Plattenepithel- und Adenokarzinomen","Comparison between squamous cell carcinoma and adenocarcinoma"],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2110"],"URL":"https:\/\/doi.org\/10.1007\/s00104-024-02110-0","relation":{},"ISSN":["2731-6971","2731-698X"],"issn-type":[{"type":"print","value":"2731-6971"},{"type":"electronic","value":"2731-698X"}],"subject":[],"published":{"date-parts":[[2024,6,11]]},"assertion":[{"value":"14 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Loew, C.\u00a0Schneider, M.\u00a0Pfl\u00fcger, R.\u00a0Mantke, K.H.\u00a0Weylandt und S.\u00a0Gretschel geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Diese retrospektive Studie erfolgte nach Konsultation der zust\u00e4ndigen Ethikkommission und im Einklang mit nationalem Recht.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}